Cancer Stem Cell & ICI Combination In Vivo Validation Service
Creative Biolabs provides a translational bridge to quantify synergy between immune checkpoint inhibitors (ICIs) and cancer stem cell (CSC)-targeted agents. We deliver mechanistic insights into how candidates "re-warm" cold tumors by restoring T-cell infiltration into protected niches. Our platform validates the reversal of MHC-I downregulation and inhibition of immunosuppressive myeloid recruitment. By neutralizing the CSC "heart" of immune evasion, we identify optimal dosing windows to prevent recurrence, ensuring your therapeutic is rigorously validated for regulatory submission.
Mechanistic Rationale: Targeting the CSC-Immune Interaction Axis
CSCs act as the primary biological "heart" of tumor immune evasion, utilizing intrinsic signaling pathways such as Hippo/YAP, Wnt, and Notch to physically exclude and chemically paralyze effector T-cells. Published research confirms that ICIs often fail in high-heterogeneity tumors because CSCs maintain a metabolically hostile, hypoxic, and MHC-I-deficient niche. These regenerative cells actively recruit immunosuppressive MDSCs and M2 macrophages to act as protective "bodyguards" against immune surveillance. By combining potent checkpoint blockade with CSC-directed therapies, Creative Biolabs assists you in "reprogramming" the tumor immunity.
Strategic Testing Solutions for Next-Generation Oncology Modalities
Our service portfolio is built upon the most advanced oncology research, focusing on the multimodal "rewiring" of the tumor microenvironment (TME). Creative Biolabs offers specialized testing for complex combination regimens to ensure your lead candidate reaches its full therapeutic potential:
Multi-Specific Antibody Evaluation
Specialized testing for bispecific and multispecific antibodies designed to simultaneously bridge CSC markers (e.g., CD44, CD133, EPCAM) and immune checkpoints (e.g., PD-1, CTLA-4, TIGIT).
Viral-Immune Priming Strategies
Validation of oncolytic viral therapies used to selectively lyse CSCs, releasing a wave of neoantigens that "warm up" the TME before ICI administration.
Metabolic Reprogramming Analysis
Assessment of metabolic modulators that alleviate the intense competition for glucose and oxygen between high-demand CSCs and infiltrating T-cells.
Adaptive Stemness Quantification
Precise monitoring to ensure that inflammatory signals triggered by ICIs do not inadvertently promote the "reprogramming" of non-stem cancer cells into a regenerative, stem-like state.
Epigenetic Reversion Testing
Evaluating the efficacy of combining ICIs with HDAC or DNMT inhibitors to unlock the "stealth mode" of quiescent CSCs and restore MHC-I expression.
Maximize Your Therapeutic Potential - Request a Technical Consultation with Our Oncology Experts
Workflow
Our workflow is meticulously designed to isolate the effects of combination therapies on the regenerative tumor core while simultaneously monitoring the restoration of a functional immune response.
Publication
This review explores how CSCs exploit immune checkpoints (ICPs) like PD-L1, CTLA-4, B7-H3, and CD47 to evade anti-tumor immunity and drive therapy resistance. It highlights the crosstalk between stemness features and ICP expression, emphasizing mechanisms of immune escape beyond conventional targets. The article also discusses emerging ICPs and combination strategies to overcome CSC-mediated immunosuppression, offering insights for next-generation immunotherapies.
Fig.1 Tumor-associated ICPs modulate stemness signaling and marker expression. 1
Why Choose Us?
Creative Biolabs leads in stem cell immunology, utilizing humanized mouse models to track human-specific immune dynamics. We precisely monitor "adaptive stemness," ensuring that inflammatory feedback loops do not create more resilient CSC populations. With 20 years of expertise, we move beyond volume measurements to include metabolic profiling and epigenetic assessment, confirming if your lead is truly curative or providing transient stabilization. Our investor-ready data packages provide a holistic view of the tumor microenvironment, helping global leaders bypass immunotherapy resistance and navigate the complexities of stem cell-mediated relapse.
Experience the Creative Biolabs Advantage - Receive a Personalized Quote for Your Project
FAQs
Why are humanized models necessary for CSC/ICI testing?
Standard syngeneic models lack human-specific CSC markers and checkpoints. Our humanized mice provide the only functional context to test human therapeutics against human tumor-initiating cells.
How does Creative Biolabs quantify CSC depletion?
We utilize limiting dilution assays (LDA), which statistically calculate the reduction in tumor-initiating cell frequency post-treatment, ensuring your drug is targeting the regenerative core.
Can we test metabolic modulators with this service?
Yes. We offer immunometabolic profiling to analyze how your candidate reverses the competition for glucose and oxygen between CSCs and activated T-cells.
Customer Review
-
Complete Eradication of Relapse-Driving Cells
Using Creative Biolabs' combination testing in our research has significantly facilitated our understanding of how CSC-targeting molecules can prevent post-ICI recurrence. The LDA data was instrumental for our Series A funding. - Dr. Al*rt S -
Exceptional Spatial Data
Using the spatial niche analysis in our research has significantly improved our ability to visualize T-cell penetration into the hypoxic core. The precision of their humanized NCG models is unmatched. - Prof. Sa*ah L
Related Services
Cancer Stem Cell & ICI Combination In Vitro Test
Creative Biolabs evaluates the CSC-immune axis, bypassing treatment-induced stemness and immunological shields. We transform "cold" tumors into hot targets for radical eradication.
Learn More →Humanized Models
Creative Biolabs offers versatile humanized mouse models with functional human immune systems. We overcome CDX/PDX limitations, providing an immunocompetent platform for high-fidelity immunotherapy preclinical testing.
Learn More →How to Contact Creative Biolabs
Creative Biolabs provides a world-class environment for validating the next frontier of cancer therapy. By integrating advanced stem cell biology with sophisticated immunology, we help you turn "temporary responses" into "durable cures."
Contact our scientific team today for a consultation on your next in vivo study.
Reference
- Hussein, Ola J., et al. "The role of immune checkpoints in modulating cancer stem cells anti-tumor immune responses: implications and perspectives in cancer therapy." Journal of Experimental & Clinical Cancer Research 44.1 (2025): 1-43. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1186/s13046-025-03514-4
Download our brochure